• The available COVID-19 vaccines may not induce neutralizing antibodies which potentially cause antibody-dependent enhancement
• Due to recent discovery of variants of SARS-CoV2 in human samples, antigenic drift is one of the key concerns
• Various types of vaccine in the market may not effectively fight against the variants
• Linear peptides containing the essential immunodominant sites of SARS-CoV2 are good candidates for the next generation of the COVID vaccine

• Linear polypeptides is used without cloning the whole S protein (Figure 1)
• Induces high titers of binding antibodies and cellular immune response hamster model
• S protein-immunodominant (S-ID) induced robust neutralizing antibody response in mice
• S-ID significantly improves disease outcome in hamsters (Figure 2)
• Application wise, these polypeptides are non-viral and easy to make. Thus, it is a very safe, new candidate for COVID-19 vaccine

Further Details

• Published in 10, 874–884 (2021)

Highly immunogenic linear peptide-based COVID-19 Vaccine

Stage of Development 

• Completed animal model study

Patents

• PCT App. No.: PCT/CN2021/090680

IP Status

• Patent application submitted